Fate Therapeutics to Present at Upcoming December Investor Conferences
Rhea-AI Summary
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced its participation in two major healthcare conferences this December. The company will join Citi's 2024 Global Healthcare Conference in Miami on December 3, featuring a panel discussion at 2:30 PM ET, and Piper Sandler's 36th Annual Healthcare Conference in New York on December 4, participating in both a panel discussion at 3:00 PM ET and a fireside chat at 4:00 PM ET. Live webcasts will be available on the company's website under Events & Presentations.
Positive
- None.
Negative
- None.
News Market Reaction – FATE
In the trading session that priced this news, FATE gained 18.28%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences:
- Citi’s 2024 Global Healthcare Conference, including a panel discussion at 2:30 PM ET on Tuesday, December 3, 2024 in Miami, Florida; and
- Piper Sandler’s 36th Annual Healthcare Conference, including a panel discussion at 3:00 PM ET and a fireside chat at 4:00 PM ET on Wednesday, December 4, 2024 in New York, New York.
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
